325 related articles for article (PubMed ID: 36951899)
1. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.
Lindsay JO; Picker N; Kromer D; Smyth M; Patel H
Curr Med Res Opin; 2023 May; 39(5):681-689. PubMed ID: 36951899
[TBL] [Abstract][Full Text] [Related]
2. Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany.
Bokemeyer B; Picker N; Kromer D; Rosin L; Patel H
Int J Colorectal Dis; 2023 May; 38(1):116. PubMed ID: 37150784
[TBL] [Abstract][Full Text] [Related]
3. Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States.
Long MD; Smith TW; Dibonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Inflamm Bowel Dis; 2020 May; 26(6):941-948. PubMed ID: 31560046
[TBL] [Abstract][Full Text] [Related]
4. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
5. Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data.
Bokemeyer B; Picker N; Wilke T; Rosin L; Patel H
Inflamm Bowel Dis; 2022 Nov; 28(11):1647-1657. PubMed ID: 35134912
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
[TBL] [Abstract][Full Text] [Related]
8. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
10. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
12. Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study.
Shin JY; Park HM; Lee MY; Jeon JY; Yoo HJ; Ye BD
Gut Liver; 2021 Nov; 15(6):867-877. PubMed ID: 33785664
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
14. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
15. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
[TBL] [Abstract][Full Text] [Related]
16. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
[TBL] [Abstract][Full Text] [Related]
17. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
18. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
[No Abstract] [Full Text] [Related]
19. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D
Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971
[TBL] [Abstract][Full Text] [Related]
20. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
